Differential effects of sigma ligands on the N-methyl-d-aspartate response in the CA1 and CA3 regions of the dorsal hippocampus: Effect of Mossy fiber lesioning

doi:10.1016/0306-4522(96)80001-7

Neuroscience

Volume 71, Issue 4, April 1996, Pages 977-987

https://doi.org/10.1016/0306-4522(96)80001-7 Get rights and content

Abstract

In the CA3 region of rat dorsal hippocampus, several σ ligands, such as 1,3-di(2-tolyl)guanidine (DTG), (+)-pentazocine and (+)-N-cyclopropylmethyl-N-methyl-1,4-diphenyl-l-ethyl-but-3-en-1-ylamine hydrochloride (JO-1784), administered intravenously at low doses, potentiate selectively the pyramidal neuron firing activity induced by microiontophoretic applications of N-methyl-d-aspartate, without affecting those induced by quisqualate, kainate or acetylcholine. A similar potentiation of the N-methyl-d-aspartate response has also been found with microiontophoretic applications of neuropeptide Y, an effect exerted via a receptors. The present experiments were carried out to determine the effects of these σ ligands and of neuropeptide Y, in the CAI and CA3 regions following unilateral destruction by a local injection of colchicine of the mossy fiber system, which is a major afference to CA3 pyramidal neurons.

In the CAI region, DTG, JO-1784 and neuropeptide Y did not potentiate the activation induced by microiontophoretic applications of N-methyl-d-aspartate. However, ( + )-pentazocine potentiated the N-methyl-d-aspartate response, similarly to its effect in the CA3 region on the intact side.

In the CA3 region, on the intact side, (+ )-pentazocine, DTG, JO-1784 and neuropeptide Y induced a selective potentiation of N-methyl-d-aspartate-induced activation, in keeping with previous reports. On the lesioned side, the effect of (+ )-pentazocine on the N-methyl-d-aspartate response was still present, but those of DTG, JO-1784 and neuropeptide Y were abolished.

These results suggest that ( + )-pentazocine, on the one hand, and DTG, JO-1784 and neuropeptide Y, on the other, are not acting on the same subtype of a receptors. Since ( + )-pentazocine, JO-1784 and neuropeptide Y have been suggested to act on the a, subtype of receptors, these data suggest the existence of two subtypes ofσ₁ receptors. They also suggest that the receptors on which DTG, JO-1784 and neuropeptide Y are acting are located on the mossy fiber terminals in the CA3 region and are absent in the CA1 region.

Reference (35)

BergeronR. et al.
Modification of the N-methyl-u-aspartate response by antidepressant sigma receptor ligands
Eur. J. Pharmac.
(1993)
ConnickJ.H. et al.
The sigma ligand 1,3-di-o-tolylguanidine depresses amino acid-induced excitation non-selectively in rat brain
Eur. J. Pharmac.
(1992)
de CostaB.R. et al.
Synthesis and evaluation of optically pure [³H]-(+)-pentazocine, a highly potent and selective radioligand for sigma receptors
Fedn Ear. biochem. Socs Lett.
(1989)
GinnS.R. et al.
Studies related to the use of colchicine as a neurotoxin in the septohippocampal cholinergic system
Brain Res.
(1992)
LooP.A. et al.
The novel anticonvulsivant MK-801 interacts with central phencyclidine recognition sites in rat brain
Eur. J. Pharmac.
(1987)
MaragosW.F. et al.
A Study of cortical and hippocampal NMDA receptors following selective cortical and subcortical lesions
Brain Res.
(1991)
McLeanS. et al.
Autoradiographic visualization of haloperidol-sensitive sigma receptors in guinea-pig brain
Neuroscience
(1988)
MonnetF.P. et al.
N-Methyl-d-aspartate-induced neuronal activation is selectively modulated by sigma receptors
Eur. J. Pharmac.
(1990)
MonnetF.P. et al.
Neuropeptide-Y selectively potentiates N-methyl-d-aspartate-induced neuronal activation
Eur. J. Pharmac.
(1990)
QuirionR. et al.
A proposal for the classification of sigma binding sites
Trends pharmac. Sci.
(1992)

RomanF.J. et al.

Neuropeptide Y and peptide YY interact with rat brain sigma and PCP binding sites

Eur. J. Pharmac.

(1989)

RothJ.E. et al.

The sigma receptor ligand 1,3-di(2-tolyl)guanidine is anticonvulsant in the rat prepiriform cortex

Eur. J. Pharmac.

(1993)

ShaughnessyL.W. et al.

Comparison of intracranial infusions of colchicine and ibotenic acid as models of neurodegeneration in the basal forebrain

Brain Res.

(1994)

SloviterR.S.

A simplified Timm stain procedure compatible with formaldehyde fixation and routine paraffin embedding in rat brain

Brain Res. Bull.

(1982)

ZhouG.Z. et al.

Computer-assisted modeling of multiple dextromethorphan and sigma binding sites in guinea pig brain

Eur. J. Pharmac.

(1991)

BlackstadT.W. et al.

Distribution of hippocampal mossy fibers in the rat: an experimental study with silver impregnation methods

J. comp. Neurol.

(1970)

BouchardP. et al.

Evidence for in vivo interactions between neuropeptide Y-related peptides and sigma receptors in the mouse hippocampal formation

J. Neurosci.

(1993)

Cited by (37)

Sigma-1 receptor in brain ischemia/reperfusion: Possible role in the NR2A-induced pathway to regulate brain-derived neurotrophic factor
2017, Journal of the Neurological Sciences
Citation Excerpt :
Therefore, they are ideally suited to upregulate a variety of processes that may affect cellular function. Although the mechanism of the interaction between σ1rs and NMDARs remains unclear, activation of σ1rs leads to the potentiation of NMDAR-mediated responses in neurons [12,13,39–44]. One possible mechanism by which NMDARs are potentiated is via the increase in the receptors expressed at the plasma membrane.
Sigma-1 receptor (σ1r) activation could attenuate the learning and memory deficits in the AD model, ischemia model and others. In our previous study, the activation of σ1r increased the expression of brain-derived neurotrophic factor (BDNF), possibly through the NR2A-induced pathway, and σ1r agonists might function as neuroprotectant agents in vascular dementia. Here, we used σ1r knockout mice to confirm the role of σ1r. Furthermore, an antagonist of NR2A was first used to investigate whether the NR2A-induced pathway is the necessary link between σ1r and BDNF. The operation of brain ischemia/reperfusion was induced by bilateral common carotid artery occlusion for 20 min in C57BL/6 and σ1r knockout mice as the ischemic group. A σ1r agonist, PRE084 (1 mg/kg, i.p.), and NR2A antagonist, PEAQX (10 mg/kg, i.p.), were administered once daily throughout the experiment. Behavioral tests were performed starting on day 8. On day 22 after brain ischemia/reperfusion, mice were sacrificed and brains were immediately collected and the injured and the hippocampus was isolated and stored at − 80 °C for western blot analysis. After ischemic operation, contrast with the σ1r knockout mice, PRE084 significantly ameliorated learning and memory impairments in the behavioral evaluation, and prevented the protein decline of BDNF, NR2A, CaMKIV and TORC1 expression in wild-type mice. However, the effects of PRE084 on CaMKIV-TORC1-CREB and BDNF, even for learning and memory impairment, were antagonized by the co-administration of PEAQX, an antagonist of NR2A. The activation of σ1r improves the impairment of learning and memory in the ischemia/reperfusion model, and the expression of BDNF, which may have been achieved through the NR2A-CaMKIV-TORC1 pathway.
Pregnenolone as a novel therapeutic candidate in schizophrenia: Emerging preclinical and clinical evidence
2011, Neuroscience
Citation Excerpt :
A number of neurosteroids demonstrate important pleiotropic actions that impact critical brain functions at physiologically relevant concentrations in rodent models. These include the modulation of inhibitory GABAergic and excitatory glutamatergic neurotransmitter systems (Wu et al., 1991; Paul and Purdy, 1992; Irwin et al., 1994; Bergeron et al., 1996; Debonnel et al., 1996; Compagnone and Mellon, 1998; Rupprecht and Holsboer, 1999; Belelli and Lambert, 2005; Belelli et al., 2006), the enhancement of neurogenesis (Mayo et al., 2005; Wang et al., 2005, 2010), microtubule assembly (Murakami et al., 2000; Fontaine-Lenoir et al., 2006; Hsu et al., 2006), dendritic outgrowth (Fontaine-Lenoir et al., 2006), and myelination (Koenig et al., 1995; Azcoitia et al., 2003; Ghoumari et al., 2003; Liao et al., 2009), regulation of the hypothalamic–pituitary–adrenal (HPA) axis (Patchev et al., 1994, 1996; Guo et al., 1995), and the reduction of apoptosis (Charalampopoulos et al., 2004, 2006; Xilouri and Papazafiri, 2006) and inflammatory responses (He et al., 2004a; VanLandingham et al., 2007; Liao et al., 2009). Many neurosteroids also exhibit pronounced neuroprotective actions against excitotoxicity (Lockhart et al., 2002; Ciriza et al., 2004; Kelley et al., 2008), neurodegeneration (Griffin et al., 2004; Ahmad et al., 2005; Xilouri and Papazafiri, 2006; Mellon et al., 2008), traumatic brain injury (TBI) (Djebaili et al., 2004, 2005; He et al., 2004b; Sayeed et al., 2009), and other insults.
Emerging preclinical and clinical evidence suggests that pregnenolone may be a promising novel therapeutic candidate in schizophrenia. Pregnenolone is a neurosteroid with pleiotropic actions in rodents that include the enhancement of learning and memory, neuritic outgrowth, and myelination. Further, pregnenolone administration results in elevations in downstream neurosteroids such as allopregnanolone, a molecule with neuroprotective effects that also increases neurogenesis, decreases apoptosis and inflammation, modulates the hypothalamic-pituitary-adrenal axis, and markedly increases GABA_A receptor responses. In addition, pregnenolone administration elevates pregnenolone sulfate, a neurosteroid that positively modulates NMDA receptors. There are thus multiple mechanistic possibilities for pregnenolone as a potential therapeutic agent in schizophrenia, including the amelioration of NMDA receptor hypofunction (via metabolism to pregnenolone sulfate) and the mitigation of GABA dysregulation (via metabolism to allopregnanolone). Additional evidence consistent with a therapeutic role for pregnenolone in schizophrenia includes neurosteroid changes following administration of certain antipsychotics in rodent models. For example, clozapine elevates pregnenolone levels in rat hippocampus, and these increases may potentially contribute to its superior antipsychotic efficacy [Marx et al. (2006a) Pharmacol Biochem Behav 84:598–608]. Further, pregnenolone levels appear to be altered in postmortem brain tissue from patients with schizophrenia compared to control subjects [Marx et al. (2006c) Neuropsychopharmacology 31:1249–1263], suggesting that neurosteroid changes may play a role in the neurobiology of this disorder and/or its treatment. Although clinical trial data utilizing pregnenolone as a therapeutic agent in schizophrenia are currently limited, initial findings are encouraging. Treatment with adjunctive pregnenolone significantly decreased negative symptoms in patients with schizophrenia or schizoaffective disorder in a pilot proof-of-concept randomized controlled trial, and elevations in pregnenolone and allopregnanolone post-treatment with this intervention were correlated with cognitive improvements [Marx et al. (2009) Neuropsychopharmacology 34:1885–1903]. Another pilot randomized controlled trial recently presented at a scientific meeting demonstrated significant improvements in negative symptoms, verbal memory, and attention following treatment with adjunctive pregnenolone, in addition to enduring effects in a small subset of patients receiving pregnenolone longer-term [Savitz (2010) Society of Biological Psychiatry Annual Meeting New Orleans, LA]. A third pilot clinical trial reported significantly decreased positive symptoms and extrapyramidal side effects following adjunctive pregnenolone, in addition to increased attention and working memory performance [Ritsner et al. (2010) J Clin Psychiatry 71:1351–1362]. Future efforts in larger cohorts will be required to investigate pregnenolone as a possible therapeutic candidate in schizophrenia, but early efforts are promising and merit further investigation.
This article is part of a Special Issue entitled: Neuroactive Steroids: Focus on Human Brain.
The cholinergic system, sigma-1 receptors and cognition
2011, Behavioural Brain Research
Citation Excerpt :
In an electrophysiological study in which animals were unilaterally lesioned by local injection of colchicine into the mossy fiber system (an afferent system to CA3 pyramidal neurons), the potentiating effect of (+)-pentazocine on the NMDA-response was found to persist on the lesioned side, but the potentiating effects of DTG and igmesine were abolished after lesioning [21]. These data were interpreted as suggesting that the test drugs were acting on two different subtypes of sigma receptors, and that the receptors for DTG and igmesine are located on the mossy fiber terminals, in contrast to the receptors for (+)-pentazocine [21]. In a later study, the effect of the sigma-2 subtype-selective ligand siramesine was tested on the neuronal response to NMDA in the CA3 region of the rat dorsal hippocampus.
This article provides an overview of present knowledge regarding the relationship between the cholinergic system and sigma-1 receptors, and discusses potential applications of sigma-1 receptor agonists in the treatment of memory deficits and cognitive disorders. Sigma-1 receptors, initially considered as a subtype of the opioid family, are unique ligand-regulated molecular chaperones in the endoplasmatic reticulum playing a modulatory role in intracellular calcium signaling and in the activity of several neurotransmitter systems, particularly the cholinergic and glutamatergic pathways. Several central nervous system (CNS) drugs show high to moderate affinities for sigma-1 receptors, including acetylcholinesterase inhibitors (donepezil), antipsychotics (haloperidol, rimcazole), selective serotonin reuptake inhibitors (fluvoxamine, sertraline) and monoamine oxidase inhibitors (clorgyline). These compounds can influence cognitive functions both via their primary targets and by activating sigma-1 receptors in the CNS. Sigma-1 agonists show powerful anti-amnesic and neuroprotective effects in a large variety of animal models of cognitive dysfunction involving, among others (i) pharmacologic target blockade (with muscarinic or NMDA receptor antagonists or p-chloroamphetamine); (ii) selective lesioning of cholinergic neurons; (iii) CNS administration of β-amyloid peptides; (iv) aging-induced memory loss, both in normal and senescent-accelerated rodents; (v) neurodegeneration induced by toxic compounds (CO, trimethyltin, cocaine), and (vi) prenatal restraint stress.
Progestogens and brain: An update
2009, Maturitas
Each synthetic progestins has its own specific activities on different tissues, which can vary significantly between progestins of different classes and even within the same class. Indeed, different progestins may support or oppose the effects of estrogen depending on the tissue, thereby supporting the concept that the clinical selection of progestins for HRT is critical in determining potential positive or detrimental effects. These actions might be particularly relevant in the central nervous system (CNS) where progesterone (P) has pivotal roles besides reproduction and sexual behavior, going from neuropsychological effects to neuroprotective functions. Growing evidence supports the idea that synthetic progestins differ significantly in their brain effects, and clinical studies indicate that these differences also occur in women. Molecular and cellular characterization of the signaling properties of synthetic progestins in brain cells is therefore required and is hoped will lead to a better clinical utilization of the available compounds, as well as to new concepts in the engineering of new molecules. The aim of the present paper is to briefly review and compare neuroendocrine effects of progestogens with special reference to P metabolism into neuroactive steroids and the opioids system.
Pregnenolone sulfate in the brain: A controversial neurosteroid
2008, Neurochemistry International
Pregnenolone sulfate (PREGS) has been shown, either at high nanomolar or at micromolar concentrations, to increase neuronal activity by inhibiting GABAergic and by stimulating glutamatergic neurotransmission. PREGS is also a potent modulator of sigma type 1 (σ1) receptors. It has been proposed that these actions of PREGS underlie its neuropharmacological effects, and in particular its influence on memory processes. On the other hand, the PREGS-mediated increase in neuronal excitability may become dangerous under particular conditions, for example in the case of excitotoxic stress or convulsions. However, the physiopathological significance of these observations has recently been put into question by the failure to detect significant levels of PREGS within the brain and plasma of rats and mice, either by direct analytical methods based on liquid chromatography/mass spectrometry (LC/MS) or enzyme linked immunosorbent assay (ELISA) with specific antibodies against PREGS, or by indirect gas chromatography/mass spectrometry (GC/MS) analysis with improved sample workup. These recent results have not come to the attention of a large number of neurobiologists interested in steroid sulfates. However, although available direct analytical methods have failed to detect levels of PREGS above 0.1–0.3 ng/g in brain tissue, it may be premature to completely exclude the local formation of biologically active PREGS within specific and limited compartments of the nervous system. In contrast to the situation in rodents, significant levels of sulfated 3β-hydroxysteroids have been measured in human plasma and brain.
Previous indirect measures of steroid sulfates by radioimmunoassays (RIA) or GC/MS had detected elevated levels of PREGS in rodent brain. The discrepancies between the results of different assay procedures have revealed the danger of indirect analysis of steroid sulfates. Indeed, PREGS must be solvolyzed/hydrolyzed prior to RIA or GC/MS analysis, and it is the released, unconjugated PREG which is then quantified. Extreme caution needs to be exercised during the preparation of samples for RIA or GC/MS analysis, because the fraction presumed to contain only steroid sulfates can be contaminated by nonpolar components from which PREG is generated by the solvolysis/hydrolysis/derivatization reactions.
Progesterone: Therapeutic opportunities for neuroprotection and myelin repair
2007, Pharmacology and Therapeutics
Citation Excerpt :
A role for the inhibition of σ1 receptor functions by progesterone has been documented in the dorsal hippocampus. Thus, the potentiation of the N-methyl-d-aspartate (NMDA) response of hippocampal neurons and the NMDA-evoked norepinephrine release from preloaded hippocampal slices by σ1 ligands, were both strongly reduced in the presence of progesterone (Monnet et al., 1995; Debonnel et al., 1996; Bergeron et al., 1999). Furthermore, progesterone has been shown to influence the behavioral efficacy of σ1 receptor ligands in mice (Phan et al., 2002; Maurice, 2004).
Progesterone and its metabolites promote the viability of neurons in the brain and spinal cord. Their neuroprotective effects have been documented in different lesion models, including traumatic brain injury (TBI), experimentally induced ischemia, spinal cord lesions and a genetic model of motoneuron disease. Progesterone plays an important role in developmental myelination and in myelin repair, and the aging nervous system appears to remain sensitive to some of progesterone's beneficial effects. Thus, the hormone may promote neuroregeneration by several different actions by reducing inflammation, swelling and apoptosis, thereby increasing the survival of neurons, and by promoting the formation of new myelin sheaths. Recognition of the important pleiotropic effects of progesterone opens novel perspectives for the treatment of brain lesions and diseases of the nervous system. Over the last decade, there have been a growing number of studies showing that exogenous administration of progesterone or some of its metabolites can be successfully used to treat traumatic brain and spinal cord injury, as well as ischemic stroke. Progesterone can also be synthesized by neurons and by glial cells within the nervous system. This finding opens the way for a promising therapeutic strategy, the use of pharmacological agents, such as ligands of the translocator protein (18 kDa) (TSPO; the former peripheral benzodiazepine receptor or PBR), to locally increase the synthesis of steroids with neuroprotective and neuroregenerative properties. A concept is emerging that progesterone may exert different actions and use different signaling mechanisms in normal and injured neural tissue.

View all citing articles on Scopus

View full text

Differential effects of sigma ligands on the N-methyl-d-aspartate response in the CA1 and CA3 regions of the dorsal hippocampus: Effect of Mossy fiber lesioning

Abstract

Eur. J. Pharmac.

Eur. J. Pharmac.

Fedn Ear. biochem. Socs Lett.

Brain Res.

Eur. J. Pharmac.

Brain Res.

Neuroscience

Eur. J. Pharmac.

Eur. J. Pharmac.

Trends pharmac. Sci.

Eur. J. Pharmac.

Eur. J. Pharmac.

Brain Res.

Brain Res. Bull.

Eur. J. Pharmac.

Distribution of hippocampal mossy fibers in the rat: an experimental study with silver impregnation methods

J. comp. Neurol.

Evidence for in vivo interactions between neuropeptide Y-related peptides and sigma receptors in the mouse hippocampal formation

J. Neurosci.